Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy

Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen

• Age 18 or older

• Ability to give signed informed consent

• Karnofsky Performance Status (KPS) at least 70

Locations
United States
Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Recruiting
Philadelphia
Contact Information
Primary
Robert Lustig, MD
PennCancerTrials@emergingmed.com
855-216-0098
Time Frame
Start Date: March 1, 2018
Estimated Completion Date: June 1, 2023
Participants
Target number of participants: 20
Treatments
Experimental: Single Arm
Dose-escalated radiation therapy
Sponsors
Leads: Abramson Cancer Center of the University of Pennsylvania

This content was sourced from clinicaltrials.gov